ES2928251A8 - Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias - Google Patents

Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias

Info

Publication number
ES2928251A8
ES2928251A8 ES202130439A ES202130439A ES2928251A8 ES 2928251 A8 ES2928251 A8 ES 2928251A8 ES 202130439 A ES202130439 A ES 202130439A ES 202130439 A ES202130439 A ES 202130439A ES 2928251 A8 ES2928251 A8 ES 2928251A8
Authority
ES
Spain
Prior art keywords
plasma
treatment
respiratory diseases
activated media
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES202130439A
Other languages
English (en)
Other versions
ES2928251B8 (es
ES2928251A1 (es
ES2928251B2 (es
Inventor
Casado Eduardo Gómez
Torres Alejandro Brun
Fernández Sandra Moreno
Macías Ana María Megía
Pérez Osvaldo Daniel Cortázar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Plasmas SL
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Medical Plasmas SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Medical Plasmas SL filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to ES202130439A priority Critical patent/ES2928251B8/es
Priority to EP22806889.6A priority patent/EP4338796A4/en
Priority to US18/290,130 priority patent/US20240350633A1/en
Priority to PCT/ES2022/070275 priority patent/WO2022238603A1/es
Publication of ES2928251A1 publication Critical patent/ES2928251A1/es
Application granted granted Critical
Publication of ES2928251B2 publication Critical patent/ES2928251B2/es
Publication of ES2928251B8 publication Critical patent/ES2928251B8/es
Publication of ES2928251A8 publication Critical patent/ES2928251A8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/08Mineral waters; Sea water
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05HPLASMA TECHNIQUE; PRODUCTION OF ACCELERATED ELECTRICALLY-CHARGED PARTICLES OR OF NEUTRONS; PRODUCTION OR ACCELERATION OF NEUTRAL MOLECULAR OR ATOMIC BEAMS
    • H05H1/00Generating plasma; Handling plasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plasma & Fusion (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES202130439A 2021-05-13 2021-05-13 Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias Active ES2928251B8 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES202130439A ES2928251B8 (es) 2021-05-13 2021-05-13 Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias
EP22806889.6A EP4338796A4 (en) 2021-05-13 2022-05-05 Plasma-activated media for use in the treatment of respiratory diseases
US18/290,130 US20240350633A1 (en) 2021-05-13 2022-05-05 Plasma-activated media for use thereof in the treatment of respiratory diseases
PCT/ES2022/070275 WO2022238603A1 (es) 2021-05-13 2022-05-05 Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES202130439A ES2928251B8 (es) 2021-05-13 2021-05-13 Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias

Publications (4)

Publication Number Publication Date
ES2928251A1 ES2928251A1 (es) 2022-11-16
ES2928251B2 ES2928251B2 (es) 2025-05-22
ES2928251B8 ES2928251B8 (es) 2026-04-08
ES2928251A8 true ES2928251A8 (es) 2026-04-09

Family

ID=84028018

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202130439A Active ES2928251B8 (es) 2021-05-13 2021-05-13 Medios activados con plasma para uso en el tratamiento de enfermedades respiratorias

Country Status (4)

Country Link
US (1) US20240350633A1 (es)
EP (1) EP4338796A4 (es)
ES (1) ES2928251B8 (es)
WO (1) WO2022238603A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140100277A1 (en) * 2012-10-05 2014-04-10 EP Technologies LLC Solutions and methods of making solutions to kill or deactivate spores, microorganisms, bacteria and fungus
US11844811B2 (en) * 2018-05-20 2023-12-19 Myfitstrip Llc Methods and compositions for alleviating respiratory dysfunction
CN111494760A (zh) * 2020-04-14 2020-08-07 西安交通大学 等离子体活性水雾化器

Also Published As

Publication number Publication date
ES2928251B8 (es) 2026-04-08
ES2928251A1 (es) 2022-11-16
WO2022238603A1 (es) 2022-11-17
EP4338796A4 (en) 2025-05-21
ES2928251B2 (es) 2025-05-22
EP4338796A1 (en) 2024-03-20
US20240350633A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
CL2018000978A1 (es) Macrociclos peptídicos contra acinetobacter baumannii
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
SV2018005704A (es) Derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina como bloqueadores de los canales task-1 y task-2 para el tratamiento de trastornos respiratorios relacionados con el sueño
MX2017015962A (es) Uso de exosomas para el tratamiento de enfermedades.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2015003140A (es) Formulaciones de enzalutamida.
MX2017009449A (es) Inhibidor jak.
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
CO6842016A2 (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer
BR112016008016A2 (pt) inibidores de kras g12c
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
UY35687A (es) Inhibidores de rorc2 y sus métodos de uso
PL3959213T3 (pl) Pirymidynowe inhibitory JAK w leczeniu chorób skóry
WO2014113407A3 (en) Use of small molecule inhibitors targeting eya tyrosine phosphatase
MX388722B (es) Compuestos para tratar el cancer de ovario.
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
PL3452100T3 (pl) Nośniki farmaceutyczne zawierające mirna do zastosowania w leczeniu chorób zwłókieniowych spowodowanych hiperglikemią
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
CL2019002145A1 (es) Composición farmacéutica que comprende betahistina.

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Effective date: 20220418

PC2A Transfer of patent

Owner name: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Effective date: 20220928

BA2A Patent application published

Ref document number: 2928251

Country of ref document: ES

Kind code of ref document: A1

Effective date: 20221116

PC2A Transfer of patent

Owner name: MEDICAL PLASMAS, S.L.

Effective date: 20230301

FG2A Definitive protection

Ref document number: 2928251

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20250522